GlassScriptPhysician profile
Mark Gary Meehlhause
NPI 1215968417
$3,742.39
in general payments reported to CMS, 2019-2025
48 companies · $560 in 2025
The $560 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $459 · 2021: $587 · 2022: $435 · 2023: $455 · 2024: $438 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $448.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $326.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $223.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $218.47 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $191.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $186.77 | 2019-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $185.03 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.69 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $141.27 | 2019-2024 | Spravato |
| Abbott Laboratories | $130.48 | 2019-2023 | Freestyle Libre 3 |
| Antares Pharma, INC. | $120.19 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.19 | 2022 | |
| Cleerly, INC. | $98.41 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Pfizer INC. | $98.14 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.13 | 2020-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Meehlhause listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.